Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors.

Publisher: BioMed Central Country of Publication: England NLM ID: 9421567 Publication Model: Electronic Cited Medium: Internet ISSN: 1423-0127 (Electronic) Linking ISSN: 10217770 NLM ISO Abbreviation: J Biomed Sci Subsets: MEDLINE

Publication: 2009- : London : BioMed Central
Original Publication: Basel ; New York : S. Karger Medical and Scientific Publishers, c1994-

Cognition/*drug effects ; Depression/*physiopathology ; Long-Term Potentiation/*drug effects ; Nanoparticles/*adverse effects ; Synaptic Transmission/*drug effects ; Zinc Oxide/*adverse effects; Animals ; Dentate Gyrus/drug effects ; Dentate Gyrus/metabolism ; Depression/chemically induced ; Disease Models, Animal ; Injections, Intraperitoneal ; Lipopolysaccharides/toxicity ; Male ; Maze Learning/drug effects ; Memory, Short-Term/drug effects ; Mice ; Nanoparticles/administration & dosage ; Perforant Pathway/drug effects ; Perforant Pathway/metabolism ; Random Allocation ; Spatial Behavior/drug effects ; Zinc Oxide/administration & dosage ; Zinc Oxide/chemistry

Background: Nanomaterials, as a new kind of materials, have been greatly applied in different fields due to their special properties. With the industrialization of nanostructured materials and increasing public exposure, the biosafety and potential influences on central nervous system (CNS) have received more attention. Nanosized zinc oxide (nanoZnO) was suggested to up-regulate neuronal excitability and to induce glutamate release in vitro. Therefore, we hypothesized nanoparticles of nanoZnO may lead to changes in balance of neurotransmitter or neuronal excitability of CNS. This study was to investigate if there were effects of nanoZnO on animal model of depression.
Methods: Male Swiss mice were given lipopolysaccharides (LPS, 100 μg/kg, 100 μg/ml, every other day, 8 times, i.p.) from weaning to induce depressive-like behaviors. NanoZnO (5.6 mg/kg, 5.6 mg/ml, every other day, 8 times, i.p.) was given as the interaction. The mouse model was characterized using the methods of open field test, tail suspension test and forced swim test. Furthermore, the spatial memory was evaluated using Morris water maze (MWM) and the synaptic plasticity was assessed by measuring the long-term potentiation (LTP) in the perforant pathway (PP) to dentate gyrus (DG) in vivo.
Results: Results indicated that model mice showed disrupted spatial memory and LTP after LPS injections and the behavioral and electrophysiological improvements after nanoZnO treatment.
Conclusion: Data suggested that nanoZnO may play some roles in CNS of mental disorders, which could provide some useful direction on the new drug exploring and clinical researches.

Nanoscale. 2010 Dec;2(12):2826-34. (PMID: 20949211)
Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92. (PMID: 11701187)
J Neurosci. 2007 Jun 20;27(25):6647-54. (PMID: 17581951)
Psychopharmacology (Berl). 1985;85(3):367-70. (PMID: 3923523)
Part Fibre Toxicol. 2010 Mar 03;7:3. (PMID: 20199661)
Environ Sci Technol. 2006 Jul 15;40(14):4374-81. (PMID: 16903273)
Trends Neurosci. 1988 Oct;11(10):465-9. (PMID: 2469166)
Brain Res Bull. 2007 Apr 2;72(1):32-43. (PMID: 17303505)
BMC Neurosci. 2008 Dec 10;9 Suppl 3:S4. (PMID: 19091001)
Neuropharmacology. 2008 Mar;54(3):530-41. (PMID: 18164735)
Pharmacol Biochem Behav. 2005 Jul;81(3):688-93. (PMID: 15982728)
Environ Sci Technol. 2007 Nov 1;41(21):7530-5. (PMID: 18044537)
J Neurochem. 2008 May;105(3):921-32. (PMID: 18182044)
Neurosci Biobehav Rev. 2005;29(4-5):891-909. (PMID: 15885777)
J Neurochem. 2000 Feb;74(2):457-71. (PMID: 10646496)
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5054-9. (PMID: 16549776)
J Physiol. 2011 Apr 15;589(Pt 8):1905-9. (PMID: 21098002)
Ann N Y Acad Sci. 2010 Jan;1184:154-72. (PMID: 20146696)
Brain. 2006 Jul;129(Pt 7):1659-73. (PMID: 16672292)
Neurochem Res. 2010 Sep;35(9):1376-83. (PMID: 20524151)
Int J Nanomedicine. 2011;6:1453-61. (PMID: 21796247)
Int J Nanomedicine. 2008;3(4):533-45. (PMID: 19337421)
Neurosci Lett. 2009 May 29;456(1):20-4. (PMID: 19429126)
Amino Acids. 2012 Jan;42(1):75-94. (PMID: 20552384)
Pharm Sci Technol Today. 2000 May;3(5):155-162. (PMID: 10785657)
Toxicol Lett. 2009 Mar 28;185(3):211-8. (PMID: 19382294)
ACS Nano. 2008 Oct 28;2(10):1987-92. (PMID: 19206442)
J R Soc Interface. 2010 Aug 6;7 Suppl 4:S411-22. (PMID: 20519209)
J Neurosci. 2006 Oct 18;26(42):10709-16. (PMID: 17050710)
Expert Opin Drug Deliv. 2010 Sep;7(9):1063-77. (PMID: 20716019)
Food Chem Toxicol. 2010 Jun;48(6):1762-6. (PMID: 20412830)
Neurotoxicology. 2009 Mar;30(2):220-30. (PMID: 19146874)
Nat Biotechnol. 2003 Oct;21(10):1166-70. (PMID: 14520401)
Langmuir. 2010 Oct 5;26(19):15399-408. (PMID: 20809599)
Environ Sci Technol. 2007 Dec 15;41(24):8484-90. (PMID: 18200883)
J Mater Sci Mater Med. 2004 Aug;15(8):847-51. (PMID: 15477735)
Science. 2006 Feb 3;311(5761):622-7. (PMID: 16456071)
Nat Rev Neurosci. 2006 Jan;7(1):65-74. (PMID: 16371951)
Neuroscience. 2010 Aug 11;169(1):214-22. (PMID: 20438813)
J Neuroinflammation. 2004 Jul 7;1(1):12. (PMID: 15285803)
Hippocampus. 2006;16(11):981-9. (PMID: 17016817)
Mol Brain. 2011 Jan 19;4:6. (PMID: 21247477)
Rev Neurosci. 2000;11(1):53-8. (PMID: 10716655)
Curr Drug Targets. 2006 Jun;7(6):643-8. (PMID: 16787165)
Curr Mol Med. 2006 Sep;6(6):651-63. (PMID: 17022735)
J Drug Target. 2001;9(4):267-79. (PMID: 11697030)
Chemosphere. 2008 Apr;71(7):1308-16. (PMID: 18194809)
J Affect Disord. 2011 Nov;134(1-3):20-31. (PMID: 21163534)
Front Aging Neurosci. 2010 Jan 04;1:6. (PMID: 20552057)
J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(12):2699-711. (PMID: 17114101)
Praxis (Bern 1994). 1998 Feb 18;87(8):263-70. (PMID: 9542454)
Folia Histochem Cytochem (Krakow). 1980;18(3):201-6. (PMID: 6110619)
Nanotoxicology. 2010 Mar;4(1):15-41. (PMID: 20795900)
Pharmacol Res. 2010 Aug;62(2):166-78. (PMID: 20153429)
Exp Neurol. 2007 Mar;204(1):1-13. (PMID: 17258711)
Nano Lett. 2006 Apr;6(4):866-70. (PMID: 16608300)
Angew Chem Int Ed Engl. 2009;48(29):5313-5. (PMID: 19544338)
J Drug Target. 2004;12(9-10):635-41. (PMID: 15621689)
Nanotechnology. 2008 Jul 23;19(29):295103. (PMID: 18836572)
Biomaterials. 2011 Nov;32(32):8218-25. (PMID: 21807406)
Brain Res Brain Res Rev. 1999 Nov;30(3):236-49. (PMID: 10567726)
Appl Phys Lett. 2007 May 24;90(213902):2139021-2139023. (PMID: 18160973)
Hippocampus. 2006;16(4):345-60. (PMID: 16302229)
Mol Psychiatry. 2009 May;14(5):511-22. (PMID: 18195714)
Exp Anim. 2010;59(2):191-7. (PMID: 20484852)
Pharmacol Rep. 2008 Sep-Oct;60(5):588-9. (PMID: 19066406)
Anal Lett. 2008 Oct;41(15):2844-2859. (PMID: 19112518)
Hippocampus. 2011 Apr;21(4):422-33. (PMID: 20087886)
Neuropsychopharmacology. 2004 Apr;29(4):770-6. (PMID: 14970834)

0 (Lipopolysaccharides)
SOI2LOH54Z (Zinc Oxide)

Date Created: 20120204 Date Completed: 20120516 Latest Revision: 20220318

20221213

PMC3305542

10.1186/1423-0127-19-14

22300475